Antengene announces ind approval in china for a global phase iii trial of selinexor in advanced or recurrent endometrial cancer

Shanghai and hong kong, may 12, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that china's national medical products administration (nmpa) has approved the investigational new drug (ind) application for a phase iii clinical trial designed to evaluate the safety and efficacy of selinexor (xpovio®) in the treatment of advanced or recurrent endometrial cancer (the siendo trial). endometrial cancer is a common gynecologic malignancy which frequently occurs in women of reproductive age.
KPTI Ratings Summary
KPTI Quant Ranking